TransMedics Group, Inc. (TMDX)
TransMedics Group, Inc. (TMDX) from its SEC filings: 2025 revenue $605.5 million (+37% vs the year before), net margin 31%, free cash flow $133.6 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Electromedical & Electrotherapeutic Apparatus |
| Revenue (2025) | $605.5 million |
| Revenue growth | +37% |
| Net income | $190.3 million |
| Net margin | 31.4% |
| Free cash flow | $133.6 million |
| Diluted EPS | $4.87 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | +21% |
| Cash | $330.1 million |
| Long-term debt | $58.8 million |
| Share count, 1 year | +2% |
| Fundamentals check | Strong fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-24. Education only, not financial advice.